ArticleScientific reports2026
Predictive modeling of influenza strain drugs using temperature-based topological indices and regression analysis via multi-criteria decision making techniques.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The proposed study is an integrated graph-theoretical and statistical model of predictive modeling and ranking of influenza strain drugs based on temperature-based topological indices. Chemical graphs were used to model drug molecules and regression models that estimated important physicochemical properties were derived. The cubic models had the best predictive ability with coefficients of determination up to [Formula: see text] of molar refractivity and polarity and [Formula: see text] of molar volume and moderate correlation of boiling and flash points ([Formula: see text]). Moreover, the multi-criteria decision-making methods (WSM and WPM) reported Azithromycin (81.25), Ritonavir (77.46), and Indinavir (72.82) as the best ranked ones. The presented solution will offer a cost-effective, interpretable, and reliable instrument of antiviral drug prioritization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.